EBV CAR-T Cells for Nasopharyngeal Carcinoma

Inclusion Criteria: * 1)Voluntarily sign written informed consent; * 2)Age ≥18, ≤75 years old, male and female; * 3 )Estimated survival ≥ 3 months; * 4\) ECOG physical fitness score was 0-2; * 5\) EBV positive nasopharyngeal carcinoma was diagnosed; * 6\) Positive target detection; * 7\) At least one measurable lesion according to RECIST V1.1 solid tumor evaluation criteria; * 8\) Patients with recurrent/metastatic nasopharyngeal carcinoma who had previously failed second-line or higher systemic therapy; * 9\) Monopheresis or venous blood collection venous access can be established, and there are no other contraindications for blood cell separation; * 10\) Full organ and bone marrow function, * 11\) Toxicity and side effects left by previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ grade 1 (CTCAE 5.0); * 12\) Fertile subjects (male or female) must use effective medical contraception during the study period and for 6 months after the end of administration. In female subjects of reproductive age, a negative pregnancy test should be performed within 72 h prior to the first dose. Exclusion Criteria: * 1\) There are active CNS metastases (except those stabilized by treatment); * 2)HIV positive, HBsAg positive, HBV DNA copy number positive (quantitative test ≥1000cps/ mL), HCV antibody positive and HCV RNA positive; * 3\) Those with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation; * 4\) subjects with severe autoimmune diseases and long-term use of immunosuppressants; * 5\) Within 14 days prior to enrollment, there were active or uncontrollable infections requiring systemic treatment; * 6\) Any unstable systemic disease * 7\) Complicated with lung, brain, kidney and other important organ dysfunction; * 8\) Subjects have undergone major surgery or trauma in the 4 weeks prior to receiving cell therapy, or are expected to undergo major surgery during the study period; * 9\) Subjects received their last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, or immunotherapy) within 4 weeks prior to receiving cell therapy; * 10\) The subject currently has or has had other malignancies that cannot be cured within 3 years, except cervical carcinoma in situ or basal cell carcinoma of the skin, and other malignancies with disease-free survival of more than 5 years; * 11\) T cells modified with chimeric antigen receptor (CAR T, TCR-T) within six months; * 12\) Combined graft versus host disease (GVHD); * 13\) Subjects who were receiving systemic steroids prior to screening and determined by the investigator to require long-term systemic steroid use during treatment (other than inhalation or topical use); And subjects who were treated with systemic steroids (except for inhalation or topical use) within 72 h prior to cell infusion; * 14\) A history of severe allergies or allergies; * 15\) Subjects requiring anticoagulant therapy; * 16\) Women who are pregnant or breast-feeding, or have a pregnancy plan within six months (for both men and women); * 17\) Researchers believe that there are other reasons not to include patients in the treatment.